Program
TE-8105
A development code. Also written as “TE-8105 MAD Cohort 1”, “TE-8105 MAD Cohort 2” and “TE-8105 MAD Cohort 3”.
Its studies are mostly in Obesity, led by Immunwork.
Furthest: phase 2, since Jun 6, 20242 company-led studies, 1 open or runningNext primary completion: Feb 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immunwork | 21 open or running | phase 2since Jun 6, 2024 | Jun 6, 2024 | Feb 2028phase 2 · NCT07857473 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 6, 2024First study: phase 2 study in OverweightFirst studyNCT06471530 · 38 enrolled · Australia
- Sep 24, 2026Phase 2 study in OverweightNCT07857473 · 204 planned · Australia
Ahead
- Feb 2028Primary completion: phase 2 study in OverweightNCT07857473
TargetBeta
GLP1R →read by rule
“TE-8105 is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist designed to help manage body weight and blood sugar levels.”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07857473Overweight · Australia | 2 | Not yet recruiting | Feb 2028 | 204 |
| NCT06471530Overweight · Australia | 2 | Completed | Jan 3, 2025 | 38 |
How it is read
Names in the registry
- “TE-8105 MAD Cohort 1”, 2 entries
- “TE-8105 MAD Cohort 2”, 2 entries
- “TE-8105 MAD Cohort 3”, 1 entry
- “TE-8105 SAD Cohort 1”, 1 entry
- “TE-8105 SAD Cohort 3”, 1 entry
Codes read as this program: TE8105.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.